Cormorant Asset Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cormorant Asset Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-500,000	Closed	-$10.1M	–	79
2017 Q1	$10.1M	Buy	500,000 +19,499	+4%	+$387K	1.46%	24
2016 Q4	$7.49M	Hold	480,501	–	–	1.01%	30
2016 Q3	$6.27M	Hold	480,501	–	–	0.69%	45
2016 Q2	$3.29M	Buy	480,501 +5,466	+1%	+$45.7K	0.47%	53
2016 Q1	$4.49M	Buy	475,035 +118,435	+33%	+$955K	0.68%	44
2015 Q4	$3.59M	Hold	356,600	–	–	0.43%	53
2015 Q3	$5.1M	Buy	+356,600	New	+$8.75M	0.82%	36

Other funds holding ZYNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FTIOP

Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Cormorant Asset Management's ZYNE Position: Q2 2017 in Review

Cormorant Asset Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2017, closing a stake of 500,000 shares — an estimated $10.1M sold.

Cormorant Asset Management first reported a position in ZYNE in Q3 2015 and held it in 7 quarters. The position peaked at $10.1M in Q1 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q2 2017.

Cormorant Asset Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
Cormorant Asset Management sold 500,000 Zynerba Pharmaceuticals, Inc shares in Q2 2017, an estimated $10.1M.
Cormorant Asset Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 7 quarters.
Cormorant Asset Management's Zynerba Pharmaceuticals, Inc position peaked at $10.1M in Q1 2017.
66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2017.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.